Thus, dysregulation of GSK3β has been implicated in nigral dopaminergic neurodegeneration [362], and its inhibition, following a consistent number of observations, has been increasingly considered as an anti-PD therapy [363]. Here, GSK3B is linked to Parkinson disease.